{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:48:58Z","timestamp":1764600538260,"version":"3.46.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The Innovation Research Project of Medical and Health Care of Suzhou","award":["CXYJ2024A07"],"award-info":[{"award-number":["CXYJ2024A07"]}]},{"name":"the Science and Technology Project of Suzhou Municipal Health Commission","award":["LCZX202234"],"award-info":[{"award-number":["LCZX202234"]}]},{"name":"the Cancer Research Society Charlotte Legare Memorial Fund","award":["Operating Grant 1055181"],"award-info":[{"award-number":["Operating Grant 1055181"]}]},{"name":"CoMRAD grant from the College of Medicine, University of Saskatchewan","award":["#1-427754"],"award-info":[{"award-number":["#1-427754"]}]},{"name":"Saskatchewan Cancer Agency Operating Grant with funds donated to the Cancer Foundation of Saskatchewan","award":["#1-425532"],"award-info":[{"award-number":["#1-425532"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-025-04217-7","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T05:35:22Z","timestamp":1763444122000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["CD40 agonist improves the therapeutic efficacy of irreversible electroporation ablation for metastatic melanoma by promoting unexpected CD8+CD103+ cDC1 and TRM cell responses"],"prefix":"10.1007","volume":"74","author":[{"given":"Zhaojia","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tauqeer","family":"Iftikhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary","family":"Groot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scot C.","family":"Leary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Baniak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahid","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Moser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junhong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jim","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"4217_CR1","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.bbrc.2008.08.060","volume":"376","author":"E Tekle","year":"2008","unstructured":"Tekle E, Wolfe MD, Oubrahim H, Chock PB (2008) Phagocytic clearance of electric field induced \u201capoptosis-mimetic\u201d cells. Biochem Biophys Res Commun 376:256\u2013260. https:\/\/doi.org\/10.1016\/j.bbrc.2008.08.060","journal-title":"Biochem Biophys Res Commun"},{"key":"4217_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1177\/153303460700600401","volume":"6","author":"B Rubinsky","year":"2007","unstructured":"Rubinsky B (2007) Irreversible electroporation in medicine. Technol Cancer Res Treat 6:255\u2013260. https:\/\/doi.org\/10.1177\/153303460700600401","journal-title":"Technol Cancer Res Treat"},{"key":"4217_CR3","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006386","volume":"96","author":"T Lyu","year":"2017","unstructured":"Lyu T, Wang X, Su Z, Shangguan J, Sun C, Figini M, Wang J, Yaghmai V, Larson AC, Zhang Z (2017) Irreversible electroporation in primary and metastatic hepatic malignancies: a review. Medicine (Baltimore) 96:e6386. https:\/\/doi.org\/10.1097\/MD.0000000000006386","journal-title":"Medicine (Baltimore)"},{"key":"4217_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.811726","volume":"12","author":"N Zhang","year":"2022","unstructured":"Zhang N, Li Z, Han X, Zhu Z, Li Z, Zhao Y, Liu Z, Lv Y (2022) Irreversible electroporation: an emerging immunomodulatory therapy on solid tumors. Front Immunol 12:811726. https:\/\/doi.org\/10.3389\/fimmu.2021.811726","journal-title":"Front Immunol"},{"issue":"Suppl 3","key":"4217_CR5","doi-asserted-by":"publisher","first-page":"S443","DOI":"10.1245\/s10434-012-2736-1","volume":"20","author":"RC Martin 2nd","year":"2013","unstructured":"Martin RC 2nd (2013) McFarland K Ellis S, Velanovich V (2013) Irreversible electroporation in locally advanced pancreatic cancer: potential improved overall survival. Ann Surg Oncol 20(Suppl 3):S443-449. https:\/\/doi.org\/10.1245\/s10434-012-2736-1","journal-title":"Ann Surg Oncol"},{"key":"4217_CR6","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jamcollsurg.2012.04.029","volume":"215","author":"TP Kingham","year":"2012","unstructured":"Kingham TP, Karkar AM, D\u2019Angelica MI, Allen PJ, Dematteo RP, Getrajdman GI et al (2012) Ablation of perivascular hepatic malignant tumors with irreversible electroporation. J Am Coll Surg 215:379\u2013387. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2012.04.029","journal-title":"J Am Coll Surg"},{"key":"4217_CR7","doi-asserted-by":"publisher","first-page":"3862","DOI":"10.1038\/s41467-021-24132-6","volume":"12","author":"BJ Burbach","year":"2021","unstructured":"Burbach BJ, O\u2019Flanagan SD, Shao Q, Young KM, Slaughter JR, Rollins MR et al (2021) Irreversible electroporation augments checkpoint immunotherapy in prostate cancer and promotes tumor antigen-specific tissue-resident memory CD8+ T cells. Nat Commun 12:3862. https:\/\/doi.org\/10.1038\/s41467-021-24132-6","journal-title":"Nat Commun"},{"key":"4217_CR8","doi-asserted-by":"publisher","first-page":"110166","DOI":"10.4251\/wjgo.v17.i9.110166","volume":"17","author":"YL Xing","year":"2025","unstructured":"Xing YL, Li HM, Pang XM, Zhang Y, Yang T, Li YH et al (2025) Irreversible electroporation combined with checkpoint blockade stimulates antitumor immune response in a hepatocellular carcinoma mouse model. World J Gastrointest Oncol. 17:110166. https:\/\/doi.org\/10.4251\/wjgo.v17.i9.110166","journal-title":"World J Gastrointest Oncol."},{"key":"4217_CR9","doi-asserted-by":"publisher","first-page":"4795","DOI":"10.2147\/JIR.S331023","volume":"14","author":"C He","year":"2021","unstructured":"He C, Sun S, Zhang Y, Li S (2021) Irreversible electroporation plus anti-PD-1 antibody versus irreversible electroporation alone for patients with locally advanced pancreatic cancer. J Inflamm Res. 14:4795\u20134807. https:\/\/doi.org\/10.2147\/JIR.S331023","journal-title":"J Inflamm Res."},{"key":"4217_CR10","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.cell.2020.02.041","volume":"180","author":"KA Fitzgerald","year":"2020","unstructured":"Fitzgerald KA, Kagan JC (2020) Toll-like receptors and the control of immunity. Cell 180:1044\u20131066. https:\/\/doi.org\/10.1016\/j.cell.2020.02.041","journal-title":"Cell"},{"key":"4217_CR11","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s00262-011-0984-8","volume":"60","author":"SM Amos","year":"2011","unstructured":"Amos SM, Pegram HJ, Westwood JA, John LB, Devaud C, Clarke CJ, Restifo NP, Smyth MJ, Darcy PK, Kershaw MH (2011) Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice. Cancer Immunol Immunother 60:671\u2013683. https:\/\/doi.org\/10.1007\/s00262-011-0984-8","journal-title":"Cancer Immunol Immunother"},{"key":"4217_CR12","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1080\/21645515.2015.1046659","volume":"11","author":"M Zhu","year":"2015","unstructured":"Zhu M, Xu W, Su H, Huang Q, Wang B (2015) Addition of CpG ODN and poly (I:C) to a standard maturation cocktail generates monocyte-derived dendritic cells and induces a potent Th1 polarization with migratory capacity. Hum Vaccin Immunother 11:1596\u20131605. https:\/\/doi.org\/10.1080\/21645515.2015.1046659","journal-title":"Hum Vaccin Immunother"},{"key":"4217_CR13","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1080\/21645515.2019.1571892","volume":"15","author":"Y Jiang","year":"2019","unstructured":"Jiang Y, Chen M, Nie H, Yuan Y (2019) PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations. Hum Vaccin Immunother 15:1111\u20131122. https:\/\/doi.org\/10.1080\/21645515.2019.1571892","journal-title":"Hum Vaccin Immunother"},{"key":"4217_CR14","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1073\/pnas.1810326116","volume":"116","author":"CE Nelson","year":"2019","unstructured":"Nelson CE, Mills LJ, McCurtain JL, Thompson EA, Seelig DM, Bhela S, Quarnstrom CF, Fife BT, Vezys V (2019) Reprogramming responsiveness to checkpoint blockade in dysfunctional CD8 T cells. Proc Natl Acad Sci USA 116:2640\u20132645. https:\/\/doi.org\/10.1073\/pnas.1810326116","journal-title":"Proc Natl Acad Sci USA"},{"key":"4217_CR15","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.anai.2021.03.003","volume":"126","author":"E Goleva","year":"2021","unstructured":"Goleva E, Lyubchenko T, Kraehenbuehl L, Lacouture ME, Leung DYM, Kern JA (2021) Our current understanding of checkpoint inhibitor therapy in cancer immunotherapy. Ann Allergy Asthma Immunol 126:630\u2013638. https:\/\/doi.org\/10.1016\/j.anai.2021.03.003","journal-title":"Ann Allergy Asthma Immunol"},{"key":"4217_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0811-x","volume":"7","author":"MJ Reilley","year":"2019","unstructured":"Reilley MJ, Morrow B, Ager CR, Liu A, Hong DS, Curran MA (2019) TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma. J Immunother Cancer 7:323. https:\/\/doi.org\/10.1186\/s40425-019-0811-x","journal-title":"J Immunother Cancer"},{"key":"4217_CR17","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2147\/ITT.S163614","volume":"7","author":"A Ara","year":"2018","unstructured":"Ara A, Ahmed KA, Xiang J (2018) Multiple effects of CD40-CD40L axis in immunity against infection and cancer. Immunotargets Ther 7:55\u201361. https:\/\/doi.org\/10.2147\/ITT.S163614","journal-title":"Immunotargets Ther"},{"key":"4217_CR18","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1038\/s41590-022-01324-w","volume":"23","author":"R Wu","year":"2022","unstructured":"Wu R, Ohara RA, Jo S, Liu TT, Ferris ST, Ou F, Kim S, Theisen DJ, Anderson DA 3rd, Wong BW et al (2022) Mechanisms of CD40-dependent cDC1 licensing beyond costimulation. Nat Immunol 23:1536\u20131550. https:\/\/doi.org\/10.1038\/s41590-022-01324-w","journal-title":"Nat Immunol"},{"key":"4217_CR19","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1200\/JCO.2006.08.3311","volume":"25","author":"RH Vonderheide","year":"2007","unstructured":"Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Hutnick NA, Sullivan P, Mahany JJ, Gallagher M, Kramer A et al (2007) Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 25:876\u2013883. https:\/\/doi.org\/10.1200\/JCO.2006.08.3311","journal-title":"J Clin Oncol"},{"key":"4217_CR20","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1126\/science.1198443","volume":"331","author":"GL Beatty","year":"2011","unstructured":"Beatty GL, Chiorean EG, Fishman MP, Saboury B, Teitelbaum UR, Sun W, Huhn RD, Song W, Li D, Sharp LL et al (2011) CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331:1612\u20131616. https:\/\/doi.org\/10.1126\/science.1198443","journal-title":"Science"},{"key":"4217_CR21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-med-062518-045435","volume":"71","author":"RH Vonderheide","year":"2020","unstructured":"Vonderheide RH (2020) CD40 agonist antibodies in cancer immunotherapy. Annu Rev Med 71:47\u201358. https:\/\/doi.org\/10.1146\/annurev-med-062518-045435","journal-title":"Annu Rev Med"},{"key":"4217_CR22","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1468956","volume":"7","author":"DL Bajor","year":"2018","unstructured":"Bajor DL, Mick R, Riese MJ, Huang AC, Sullivan B, Richman LP et al (2018) Long-term outcomes of a phase I study of agonist CD40 antibody and CTLA-4 blockade in patients with metastatic melanoma. Oncoimmunology. 7:e1468956. https:\/\/doi.org\/10.1080\/2162402X.2018.1468956","journal-title":"Oncoimmunology."},{"key":"4217_CR23","doi-asserted-by":"publisher","first-page":"3516","DOI":"10.1073\/pnas.0400525101","volume":"101","author":"K Tabeta","year":"2004","unstructured":"Tabeta K, Georgel P, Janssen E, Du X, Hoebe K, Crozat K et al (2004) Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc Natl Acad Sci U S A. 101:3516\u201321. https:\/\/doi.org\/10.1073\/pnas.0400525101","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"4","key":"4217_CR24","doi-asserted-by":"publisher","first-page":"645","DOI":"10.5009\/gnl210311","volume":"16","author":"CY Lim","year":"2021","unstructured":"Lim CY, Chang JH, Lee WS, Kim J, Park IY (2021) CD40 agonists alter the pancreatic cancer microenvironment by shifting the macrophage phenotype toward M1 and suppress human pancreatic cancer in organotypic slice cultures. Gut Liver. 16(4):645\u2013659. https:\/\/doi.org\/10.5009\/gnl210311","journal-title":"Gut Liver."},{"issue":"9","key":"4217_CR25","doi-asserted-by":"publisher","first-page":"2206873","DOI":"10.1002\/advs.202206873","volume":"10","author":"HC Liu","year":"2023","unstructured":"Liu HC, Gonzalez DD, Viswanath DI, Vander Pol RS, Saunders SZ, Trani ND et al (2023) Sustained intratumoral administration of agonist CD40 antibody overcomes immunosuppressive tumor microenvironment in pancreatic cancer. Adv Sci (Weinh). 10(9):2206873. https:\/\/doi.org\/10.1002\/advs.202206873","journal-title":"Adv Sci (Weinh)."},{"issue":"2","key":"4217_CR26","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0008-8749(03)00060-1","volume":"221","author":"R Sartorius","year":"2003","unstructured":"Sartorius R, D\u2019Apice L, Barba P, Guardiola J, Santoni A, Velotti F, De Berardinis P (2003) Induction of human NK cell-mediated cytotoxicity by CD40 triggering on antigen presentingcells. Cell Immunol 221(2):81\u201388","journal-title":"Cell Immunol"},{"key":"4217_CR27","doi-asserted-by":"publisher","first-page":"5821","DOI":"10.4049\/jimmunol.1400404","volume":"192","author":"JM Weiss","year":"2014","unstructured":"Weiss JM, Subleski JJ, Back T, Chen X, Watkins SK, Yagita H et al (2014) Regulatory T cells and myeloid-derived suppressor cells in the tumor microenvironment undergo Fas-dependent cell death during IL-2\/\u03b1CD40 therapy. J Immunol. 192:5821\u20139. https:\/\/doi.org\/10.4049\/jimmunol.1400404","journal-title":"J Immunol."},{"key":"4217_CR28","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1158\/2326-6066.CIR-17-0341","volume":"5","author":"D Mittal","year":"2017","unstructured":"Mittal D, Vijayan D, Putz EM, Aguilera AR, Markey KA, Straube J et al (2017) Interleukin-12 from CD103+ Batf3-dependent dendritic cells required for NK-cell suppression of metastasis. Cancer Immunol Res. 5:1098\u20131108. https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0341","journal-title":"Cancer Immunol Res."},{"key":"4217_CR29","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1084\/jem.192.6.823","volume":"192","author":"H Hochrein","year":"2000","unstructured":"Hochrein H, O\u2019Keeffe M, Luft T, Vandenabeele S, Grumont RJ, Maraskovsky E, Shortman K (2000) Interleukin (IL)-4 is a major regulatory cytokine governing bioactive IL-12 production by mouse and human dendritic cells. J Exp Med. 192:823\u201333. https:\/\/doi.org\/10.1084\/jem.192.6.823","journal-title":"J Exp Med."},{"key":"4217_CR30","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","volume":"172","author":"JP B\u00f6ttcher","year":"2018","unstructured":"B\u00f6ttcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrerizo M, Sammicheli S et al (2018) NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell 172:1022-1037.e14. https:\/\/doi.org\/10.1016\/j.cell.2018.01.004","journal-title":"Cell"},{"key":"4217_CR31","doi-asserted-by":"publisher","first-page":"77","DOI":"10.7555\/JBR.36.20210163","volume":"36","author":"PK Dhanyamraju","year":"2022","unstructured":"Dhanyamraju PK, Patel TN (2022) Melanoma therapeutics: a literature review. J Biomed Res 36:77\u201397. https:\/\/doi.org\/10.7555\/JBR.36.20210163","journal-title":"J Biomed Res"},{"issue":"Suppl 6","key":"4217_CR32","doi-asserted-by":"publisher","first-page":"vil","DOI":"10.1093\/annonc\/mdp252","volume":"20","author":"RM MacKie","year":"2009","unstructured":"MacKie RM, Hauschild A, Eggermont AM (2009) Epidemiology of invasive cutaneous melanoma. Ann Oncol. 20(Suppl 6):vil\u20137. https:\/\/doi.org\/10.1093\/annonc\/mdp252","journal-title":"Ann Oncol."},{"key":"4217_CR33","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.hoc.2009.03.013","volume":"23","author":"LM Duncan","year":"2009","unstructured":"Duncan LM (2009) The classification of cutaneous melanoma. Hematol Oncol Clin North Am 23:501\u2013513. https:\/\/doi.org\/10.1016\/j.hoc.2009.03.013","journal-title":"Hematol Oncol Clin North Am"},{"key":"4217_CR34","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.2217\/imt-2017-0096","volume":"9","author":"DA Canton","year":"2017","unstructured":"Canton DA, Shirley S, Wright J, Connolly R, Burkart C, Mukhopadhyay A, Twitty C, Qattan KE, Campbell JS, Le MH et al (2017) Melanoma treatment with intratumoral electroporation of tavokinogene telseplasmid (pIL-12, tavokinogene telseplasmid). Immunotherapy 9:1309\u20131321. https:\/\/doi.org\/10.2217\/imt-2017-0096","journal-title":"Immunotherapy"},{"key":"4217_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0638-5","volume":"7","author":"L Pasquet","year":"2019","unstructured":"Pasquet L, Bellard E, Chabot S, Markelc B, Rols MP, Teissie J, Golzio M (2019) Pre-clinical investigation of the synergy effect of interleukin-12 gene-electro-transfer during partially irreversible electropermeabilization against melanoma. J Immunother Cancer 7:161. https:\/\/doi.org\/10.1186\/s40425-019-0638-5","journal-title":"J Immunother Cancer"},{"key":"4217_CR36","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/8852233","volume":"2021","author":"A Lasarte-Cia","year":"2021","unstructured":"Lasarte-Cia A, Lozano T, Cano D, Martin-Otal C, Navarro F, Gorraiz M, Casares N, Vivas I, Lasarte JJ (2021) Intratumoral STING agonist injection combined with irreversible electroporation delays tumor growth in a model of hepatocarcinoma. BioMed Res Int 2021:8852233. https:\/\/doi.org\/10.1155\/2021\/8852233","journal-title":"BioMed Res Int"},{"key":"4217_CR37","doi-asserted-by":"publisher","first-page":"2632","DOI":"10.1038\/s41423-021-00796-4","volume":"18","author":"F Babikr","year":"2021","unstructured":"Babikr F, Wan J, Xu A, Wu Z, Ahmed S, Freywald A, Chibbar R, Wu Y, Moser M, Groot G et al (2021) Distinct roles but cooperative effect of TLR3\/9 agonists and PD-1 blockade in converting the immunotolerant microenvironment of irreversible electroporation-ablated tumors. Cell Mol Immunol 18:2632\u20132647. https:\/\/doi.org\/10.1038\/s41423-021-00796-4","journal-title":"Cell Mol Immunol"},{"key":"4217_CR38","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1600-065X.2009.00765.x","volume":"229","author":"C Wang","year":"2009","unstructured":"Wang C, Lin GH, McPherson AJ, Watts TH (2009) Immune regulation by 4\u20131BB and 4\u20131BBL: complexities and challenges. Immunol Rev 229:192\u2013215. https:\/\/doi.org\/10.1111\/j.1600-065X.2009.00765.x","journal-title":"Immunol Rev"},{"key":"4217_CR39","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1084\/jem.20171068","volume":"215","author":"AV Menk","year":"2018","unstructured":"Menk AV, Scharping NE, Rivadeneira DB, Calderon MJ, Watson MJ, Dunstane D, Watkins SC, Delgoffe GM (2018) 4\u20131BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses. J Exp Med 215:1091\u20131100. https:\/\/doi.org\/10.1084\/jem.20171068","journal-title":"J Exp Med"},{"key":"4217_CR40","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/s41423-018-0184-y","volume":"16","author":"A Xu","year":"2019","unstructured":"Xu A, Zhang L, Yuan J, Babikr F, Freywald A, Chibbar R, Moser M, Zhang W, Zhang B, Fu Z et al (2019) TLR9 agonist enhances radiofrequency ablation-induced CTL responses, leading to the potent inhibition of primary tumor growth and lung metastasis. Cell Mol Immunol 16:820\u2013832. https:\/\/doi.org\/10.1038\/s41423-018-0184-y","journal-title":"Cell Mol Immunol"},{"key":"4217_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-008026","volume":"12","author":"Y Wang","year":"2024","unstructured":"Wang Y, Zhu T, Shi Q, Zhu G, Zhu S, Hou F (2024) Tumor-draining lymph nodes: opportunities, challenges, and future directions in colorectal cancer immunotherapy. J Immunother Cancer 12:e008026. https:\/\/doi.org\/10.1136\/jitc-2023-008026","journal-title":"J Immunother Cancer"},{"key":"4217_CR42","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3389\/fimmu.2019.00009","volume":"10","author":"JC Cancel","year":"2019","unstructured":"Cancel JC, Crozat K, Dalod M, Mattiuz R (2019) Are conventional type 1 dendritic cells critical for protective antitumor immunity and how? Front Immunol 10:9. https:\/\/doi.org\/10.3389\/fimmu.2019.00009","journal-title":"Front Immunol"},{"key":"4217_CR43","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13062-023-00430-5","volume":"18","author":"P Liu","year":"2023","unstructured":"Liu P, Zhao L, Kroemer G, Kepp O (2023) Conventional type 1 dendritic cells (cDC1) in cancer immunity. Biol Direct 18:71. https:\/\/doi.org\/10.1186\/s13062-023-00430-5","journal-title":"Biol Direct"},{"key":"4217_CR44","doi-asserted-by":"publisher","first-page":"6287","DOI":"10.4049\/jimmunol.1004036","volume":"186","author":"K Fujimoto","year":"2011","unstructured":"Fujimoto K, Karuppuchamy T, Takemura N, Shimohigoshi M, Machida T, Haseda Y, Aoshi T, Ishii KJ, Akira S, Uematsu S (2011) A new subset of CD103+CD8alpha+ dendritic cells in the small intestine expresses TLR3, TLR7, and TLR9 and induces Th1 response and CTL activity. J Immunol 186:6287\u20136295. https:\/\/doi.org\/10.4049\/jimmunol.1004036","journal-title":"J Immunol"},{"key":"4217_CR45","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2103730118","author":"Y Nakajima","year":"2021","unstructured":"Nakajima Y, Chamoto K, Oura T, Honjo T (2021) Critical role of the CD44 low CD62L low CD8 + T cell subset in restoring antitumor immunity in aged mice. Proc Natl Acad Sci U S A. https:\/\/doi.org\/10.1073\/pnas.2103730118","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4217_CR46","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.3389\/fimmu.2018.02810","volume":"9","author":"A Molodtsov","year":"2018","unstructured":"Molodtsov A, Turk MJ (2018) Tissue resident CD8 memory T cell responses in cancer and autoimmunity. Front Immunol 9:2810. https:\/\/doi.org\/10.3389\/fimmu.2018.02810","journal-title":"Front Immunol"},{"key":"4217_CR47","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1038\/ni.2568","volume":"14","author":"JM Schenkel","year":"2013","unstructured":"Schenkel JM, Fraser KA, Vezys V, Masopust D (2013) Sensing and alarm function of resident memory CD8(+) T cells. Nat Immunol 14:509\u2013513. https:\/\/doi.org\/10.1038\/ni.2568","journal-title":"Nat Immunol"},{"key":"4217_CR48","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1126\/science.1254536","volume":"346","author":"JM Schenkel","year":"2014","unstructured":"Schenkel JM, Fraser KA, Beura LK, Pauken KE, Vezys V, Masopust D (2014) T cell memory. Resident memory CD8 T cells trigger protective innate and adaptive immune responses. Science 346:98\u2013101. https:\/\/doi.org\/10.1126\/science.1254536","journal-title":"Science"},{"issue":"2117\u20132132","key":"4217_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2021.08.019","volume":"54","author":"AK Molodtsov","year":"2021","unstructured":"Molodtsov AK, Khatwani N, Vella JL, Lewis KA, Zhao Y, Han J, Sullivan DE, Searles TG, Preiss NK, Shabaneh TB et al (2021) Resident memory CD8(+) T cells in regional lymph nodes mediate immunity to metastatic melanoma. Immunity 54(2117\u20132132):e2117. https:\/\/doi.org\/10.1016\/j.immuni.2021.08.019","journal-title":"Immunity"},{"key":"4217_CR50","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/ni.3775","volume":"18","author":"AP Ganesan","year":"2017","unstructured":"Ganesan AP, Clarke J, Wood O, Garrido-Martin EM, Chee SJ, Mellows T, Samaniego-Castruita D, Singh D, Seumois G, Alzetani A et al (2017) Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer. Nat Immunol 18:940\u2013950. https:\/\/doi.org\/10.1038\/ni.3775","journal-title":"Nat Immunol"},{"key":"4217_CR51","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1007\/s00262-020-02568-x","volume":"69","author":"M Nielsen","year":"2020","unstructured":"Nielsen M, Krarup-Hansen A, Hovgaard D, Petersen MM, Loya AC, Westergaard MCW, Svane IM, Junker N (2020) In vitro 4\u20131BB stimulation promotes expansion of CD8(+) tumor-infiltrating lymphocytes from various sarcoma subtypes. Cancer Immunol Immunother 69:2179\u20132191. https:\/\/doi.org\/10.1007\/s00262-020-02568-x","journal-title":"Cancer Immunol Immunother"},{"key":"4217_CR52","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41423-023-00986-2","volume":"20","author":"Q Liu","year":"2023","unstructured":"Liu Q, Ran L, Yue Z, Su X, Wang L, Wen S, Lei S, Yang X, Zhang Y, Hu J et al (2023) Tumor-specific memory CD8(+) T cells are strictly resident in draining lymph nodes during tumorigenesis. Cell Mol Immunol 20:423\u2013426. https:\/\/doi.org\/10.1038\/s41423-023-00986-2","journal-title":"Cell Mol Immunol"},{"key":"4217_CR53","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.3390\/cells10092234","volume":"10","author":"A Beumer-Chuwonpad","year":"2021","unstructured":"Beumer-Chuwonpad A, Taggenbrock R, Ngo TA, van Gisbergen K (2021) The potential of tissue-resident memory T cells for adoptive immunotherapy against cancer. Cells 10:2234. https:\/\/doi.org\/10.3390\/cells10092234","journal-title":"Cells"},{"key":"4217_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13030515","volume":"13","author":"S Jung","year":"2021","unstructured":"Jung S, Baek JH (2021) The potential of T cell factor 1 in sustaining CD8(+) T lymphocyte-directed anti-tumor immunity. Cancers (Basel) 13:515. https:\/\/doi.org\/10.3390\/cancers13030515","journal-title":"Cancers (Basel)"},{"issue":"1","key":"4217_CR55","doi-asserted-by":"publisher","first-page":"155","DOI":"10.4049\/jimmunol.2100452","volume":"208","author":"A Xu","year":"2022","unstructured":"Xu A, Leary SC, Islam MF, Wu Z, Bhanumathy KK, Ara A, Chibbar R, Fleywald A, Ahmed KA, Xiang J (2022) Prosurvival IL-7\u2013stimulated weak strength of mTORC1-S6K controls T cell memory via transcriptional FOXO1\u2013TCF1\u2013Id3 and metabolic AMPK\u03b11\u2013ULK1\u2013ATG7 pathways. J Immunol 208(1):155\u2013168. https:\/\/doi.org\/10.4049\/jimmunol.2100452","journal-title":"J Immunol"},{"issue":"17","key":"4217_CR56","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23179534","volume":"23","author":"A Ara","year":"2022","unstructured":"Ara A, Wu Z, Xu A, Ahmed KA, Leary SC, Islam MF, Chibbar R, Wu Y, Xiang J (2022) The critical role of AMPK\u03b11 in regulating autophagy and mitochondrial respiration in IL-15-stimulated mtorc1weak signal-induced T cell memory: an interplay between Yin (AMPK\u03b11) and Yang (mTORC1) energy sensors in T cell differentiation. Int J Mol Sci 23(17):9534. https:\/\/doi.org\/10.3390\/ijms23179534","journal-title":"Int J Mol Sci"},{"issue":"10","key":"4217_CR57","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/s41423-022-00879-w","volume":"19","author":"J Huang","year":"2022","unstructured":"Huang J, Leary S, Xiang J (2022) Distinct strengths of mTORC1 control T-cell memory via transcriptional FOXO1 and metabolic AMPK\u03b11 pathways in linear cell differentiation and asymmetric cell division models. Cell Mol Immunol 19(10):1073\u20131076. https:\/\/doi.org\/10.1038\/s41423-022-00879-w","journal-title":"Cell Mol Immunol"},{"key":"4217_CR58","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3390\/ijms23010037","volume":"23","author":"A Ara","year":"2021","unstructured":"Ara A, Xu A, Ahmed KA, Leary SC, Islam MF, Wu Z, Chibbar R, Xiang J (2021) The energy sensor AMPKalpha1 is critical in rapamycin-inhibition of mTORC1-S6K-induced T-cell memory. Int J Mol Sci 23:37. https:\/\/doi.org\/10.3390\/ijms23010037","journal-title":"Int J Mol Sci"},{"key":"4217_CR59","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/14737140.2017.1270208","volume":"17","author":"GL Beatty","year":"2017","unstructured":"Beatty GL, Li Y, Long KB (2017) Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists. Expert Rev Anticancer Ther 17:175\u2013186. https:\/\/doi.org\/10.1080\/14737140.2017.1270208","journal-title":"Expert Rev Anticancer Ther"},{"key":"4217_CR60","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006133","volume":"11","author":"JS Shankara Narayanan","year":"2023","unstructured":"Shankara Narayanan JS, Hayashi T, Erdem S, McArdle S, Tiriac H, Ray P, Pu M, Mikulski Z, Miller A, Messer K et al (2023) Treatment of pancreatic cancer with irreversible electroporation and intratumoral CD40 antibody stimulates systemic immune responses that inhibit liver metastasis in an orthotopic model. J Immunother Cancer 11:e006133. https:\/\/doi.org\/10.1136\/jitc-2022-006133","journal-title":"J Immunother Cancer"},{"key":"4217_CR61","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1158\/2326-6066.CIR-14-0226","volume":"3","author":"A Zippelius","year":"2015","unstructured":"Zippelius A, Schreiner J, Herzig P, Muller P (2015) Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment. Cancer Immunol Res 3:236\u2013244. https:\/\/doi.org\/10.1158\/2326-6066.CIR-14-0226","journal-title":"Cancer Immunol Res"},{"key":"4217_CR62","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1158\/2326-6066.CIR-18-0061","volume":"7","author":"HS Ma","year":"2019","unstructured":"Ma HS, Poudel B, Torres ER, Sidhom JW, Robinson TM, Christmas B, Scott B, Cruz K, Woolman S, Wall VZ et al (2019) A CD40 agonist and PD-1 antagonist antibody reprogram the microenvironment of nonimmunogenic tumors to allow T-cell-mediated anticancer activity. Cancer Immunol Res 7:428\u2013442. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0061","journal-title":"Cancer Immunol Res"},{"key":"4217_CR63","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1158\/1078-0432.CCR-23-0475","volume":"30","author":"SA Weiss","year":"2024","unstructured":"Weiss SA, Sznol M, Shaheen M, Berciano-Guerrero MA, Couselo EM, Rodr\u00edguez-Abreu D et al (2024) A Phase II trial of the CD40 agonistic antibody sotigalimab (APX005M) in combination with nivolumab in subjects with metastatic melanoma with confirmed disease progression on anti-PD-1 therapy. Clin Cancer Res. 30:74\u201381. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0475","journal-title":"Clin Cancer Res."},{"key":"4217_CR64","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1158\/1078-0432.CCR-17-2257","volume":"24","author":"J Edwards","year":"2018","unstructured":"Edwards J, Wilmott JS, Madore J, Gide TN, Quek C, Tasker A, Ferguson A, Chen J, Hewavisenti R, Hersey P et al (2018) CD103(+) tumor-resident CD8(+) T cells are associated with improved survival in immunotherapy-naive melanoma patients and expand significantly during anti-PD-1 treatment. Clin Cancer Res 24:3036\u20133045. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2257","journal-title":"Clin Cancer Res"},{"key":"4217_CR65","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nri3405","volume":"13","author":"L Chen","year":"2013","unstructured":"Chen L, Flies DB (2013) Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 13:227\u2013242. https:\/\/doi.org\/10.1038\/nri3405","journal-title":"Nat Rev Immunol"},{"key":"4217_CR66","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1158\/2159-8290.CD-22-1029","volume":"13","author":"I Melero","year":"2023","unstructured":"Melero I, Sanmamed MF, Glez-Vaz J, Luri-Rey C, Wang J, Chen L (2023) CD137 (4\u20131BB)-based cancer immunotherapy on its 25th anniversary. Cancer Discov 13:552\u2013569. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-1029","journal-title":"Cancer Discov"},{"key":"4217_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-022-00866-3","volume":"29","author":"A Tiwari","year":"2022","unstructured":"Tiwari A, Trivedi R, Lin SY (2022) Tumor microenvironment: barrier or opportunity towards effective cancer therap. J Biomed Sci 29:83","journal-title":"J Biomed Sci"},{"key":"4217_CR68","doi-asserted-by":"publisher","DOI":"10.48101\/ujms.v126.6118","volume":"126","author":"V Milosevica","year":"2021","unstructured":"Milosevica V, \u00d6stman A (2021) Interactions between cancer-associated fibroblasts and T-cells: functional crosstalk with targeting and biomarker potential. UPSALA J Med Sci 126:e6118. https:\/\/doi.org\/10.48101\/ujms.v126.6118","journal-title":"UPSALA J Med Sci"},{"issue":"46","key":"4217_CR69","doi-asserted-by":"publisher","first-page":"19455","DOI":"10.1073\/pnas.0909474106","volume":"106","author":"JM Weiss","year":"2009","unstructured":"Weiss JM, Back TC, Scarzello AJ, Subleski JJ, Hall VL, Stauffer JK et al (2009) Successful immunotherapy with IL-2\/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment. Proc Natl Acad Sci U S A. 106(46):19455\u201360. https:\/\/doi.org\/10.1073\/pnas.0909474106","journal-title":"Proc Natl Acad Sci U S A."},{"key":"4217_CR70","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202300549","volume":"13","author":"Y Kim","year":"2024","unstructured":"Kim Y, Lee S, Jon S (2024) Liposomal delivery of an immunostimulatory CpG induces robust antitumor immunity and long-term immune memory by reprogramming tumor-associated macrophages. Adv Healthc Mater. 13:e2300549. https:\/\/doi.org\/10.1002\/adhm.202300549","journal-title":"Adv Healthc Mater."},{"key":"4217_CR71","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1002\/cam4.1518","volume":"7","author":"P Dhupkar","year":"2018","unstructured":"Dhupkar P, Gordon N, Stewart J, Kleinerman ES (2018) Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases. Cancer Med 7:2654\u20132664. https:\/\/doi.org\/10.1002\/cam4.1518","journal-title":"Cancer Med"},{"key":"4217_CR72","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41591-019-0522-3","volume":"25","author":"KE Yost","year":"2019","unstructured":"Yost KE, Satpathy AT, Wells DK, Qi Y, Wang C, Kageyama R et al (2019) Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat Med 25:1251\u20131259. https:\/\/doi.org\/10.1038\/s41591-019-0522-3","journal-title":"Nat Med"},{"key":"4217_CR73","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.cell.2023.02.021","volume":"186","author":"MK Rahim","year":"2023","unstructured":"Rahim MK, Okholm YLH, Jones KB, Algazi AP, Hal P, Spitzer MH et al (2023) Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes. Cell 186:1127\u20131143. https:\/\/doi.org\/10.1016\/j.cell.2023.02.021","journal-title":"Cell"},{"key":"4217_CR74","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1016\/j.cell.2022.09.020","volume":"185","author":"Q Huang","year":"2022","unstructured":"Huang Q, Wu X, Wang Z, Chen X, Wang L, Lu Y et al (2022) The primordial differentiation of tumor-specific memory CD8+ T cells as bona fide responders to PD-1\/PD-L1 blockade in draining lymph nodes. Cell 185:4049-4066.e25. https:\/\/doi.org\/10.1016\/j.cell.2022.09.020","journal-title":"Cell"},{"key":"4217_CR75","doi-asserted-by":"publisher","first-page":"1298041","DOI":"10.3389\/fimmu.2023.1298041","volume":"14","author":"C Yi","year":"2024","unstructured":"Yi C, Zhang H, Yang J, Chen D, Jiang S (2024) Elucidating common pathogenic transcriptional networks in infective endocarditis and sepsis: integrated insights from biomarker discovery and single-cell RNA sequencing. Front Immunol. 14:1298041. https:\/\/doi.org\/10.3389\/fimmu.2023.1298041","journal-title":"Front Immunol."}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04217-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-025-04217-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-025-04217-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T14:45:28Z","timestamp":1764600328000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-025-04217-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":75,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4217"],"URL":"https:\/\/doi.org\/10.1007\/s00262-025-04217-7","relation":{},"ISSN":["1432-0851"],"issn-type":[{"type":"electronic","value":"1432-0851"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"26 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"378"}}